Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 1;101(7):1372–1378. doi: 10.1172/JCI930

Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.

B M Mueller 1, W Ruf 1
PMCID: PMC508714  PMID: 9525979

Abstract

Tissue factor (TF), the initiating cell surface receptor of the coagulation cascade, plays important roles in embryogenesis, angiogenesis, and tumor cell metastasis. It is controversial whether proteolytic function of TF complexed with its serine protease ligand VIIa is required for metastatic tumor dissemination. We show here in a model for TF-dependent experimental hematogenous metastasis, that TF supports metastasis by both proteolytic activity of the TF-VIIa complex and currently undefined functions of the cytoplasmic domain. We demonstrate that ligand binding of VIIa to TF is required for metastasis. Antimetastatic properties of covalently inactivated VIIa provide evidence that ligand binding is insufficient per se to support metastasis, emphasizing that proteolytic activity is necessary for the metastatic process. Ala or Asp mutations of cytoplasmic serine residues were introduced to preclude or mimic phosphorylation. In vivo analysis of these mutants suggests that local protease generation on the tumor cell surface does not serve simply to activate the cytoplasmic domain of TF by serine phosphorylation. Thus, extracellular functions of the catalytically active TF-VIIa complex cooperate with specific functions of the TF cytoplasmic domain to support the complex process of hematogenous tumor cell dissemination.

Full Text

The Full Text of this article is available as a PDF (194.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bromberg M. E., Konigsberg W. H., Madison J. F., Pawashe A., Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8205–8209. doi: 10.1073/pnas.92.18.8205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brooks P. C., Strömblad S., Sanders L. C., von Schalscha T. L., Aimes R. T., Stetler-Stevenson W. G., Quigley J. P., Cheresh D. A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996 May 31;85(5):683–693. doi: 10.1016/s0092-8674(00)81235-0. [DOI] [PubMed] [Google Scholar]
  3. Bugge T. H., Xiao Q., Kombrinck K. W., Flick M. J., Holmbäck K., Danton M. J., Colbert M. C., Witte D. P., Fujikawa K., Davie E. W. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6258–6263. doi: 10.1073/pnas.93.13.6258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carmeliet P., Mackman N., Moons L., Luther T., Gressens P., Van Vlaenderen I., Demunck H., Kasper M., Breier G., Evrard P. Role of tissue factor in embryonic blood vessel development. Nature. 1996 Sep 5;383(6595):73–75. doi: 10.1038/383073a0. [DOI] [PubMed] [Google Scholar]
  5. Chambers A. F., MacDonald I. C., Schmidt E. E., Koop S., Morris V. L., Khokha R., Groom A. C. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 1995 Dec;14(4):279–301. doi: 10.1007/BF00690599. [DOI] [PubMed] [Google Scholar]
  6. Dittmar S., Ruf W., Edgington T. S. Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation. Biochem J. 1997 Feb 1;321(Pt 3):787–793. doi: 10.1042/bj3210787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ellis V., Pyke C., Eriksen J., Solberg H., Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci. 1992 Dec 4;667:13–31. doi: 10.1111/j.1749-6632.1992.tb51591.x. [DOI] [PubMed] [Google Scholar]
  8. Esumi N., Fan D., Fidler I. J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 1991 Sep 1;51(17):4549–4556. [PubMed] [Google Scholar]
  9. Fidler I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990 Oct 1;50(19):6130–6138. [PubMed] [Google Scholar]
  10. Fischer E. G., Ruf W., Mueller B. M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res. 1995 Apr 15;55(8):1629–1632. [PubMed] [Google Scholar]
  11. Fuster V., Badimon J., Chesebro J. H., Fallon J. T. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis. 1996 Oct;26 (Suppl 4):269–284. doi: 10.1159/000217308. [DOI] [PubMed] [Google Scholar]
  12. Gasic G. J., Iwakawa A., Gasic T. B., Viner E. D., Milas L. Leech salivary gland extract from Haementeria officinalis, a potent inhibitor of cyclophosphamide- and radiation-induced artificial metastasis enhancement. Cancer Res. 1984 Dec;44(12 Pt 1):5670–5676. [PubMed] [Google Scholar]
  13. Grandaliano G., Valente A. J., Abboud H. E. A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production. J Exp Med. 1994 May 1;179(5):1737–1741. doi: 10.1084/jem.179.5.1737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996 Dec 1;56(23):5309–5318. [PubMed] [Google Scholar]
  15. Hartwig J. H., Bokoch G. M., Carpenter C. L., Janmey P. A., Taylor L. A., Toker A., Stossel T. P. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell. 1995 Aug 25;82(4):643–653. doi: 10.1016/0092-8674(95)90036-5. [DOI] [PubMed] [Google Scholar]
  16. Klepfish A., Greco M. A., Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993 Apr 1;53(6):978–982. doi: 10.1002/ijc.2910530620. [DOI] [PubMed] [Google Scholar]
  17. Lum H., Andersen T. T., Siflinger-Birnboim A., Tiruppathi C., Goligorsky M. S., Fenton J. W., 2nd, Malik A. B. Thrombin receptor peptide inhibits thrombin-induced increase in endothelial permeability by receptor desensitization. J Cell Biol. 1993 Mar;120(6):1491–1499. doi: 10.1083/jcb.120.6.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mackman N. Regulation of the tissue factor gene. FASEB J. 1995 Jul;9(10):883–889. doi: 10.1096/fasebj.9.10.7615158. [DOI] [PubMed] [Google Scholar]
  19. Masuda M., Nakamura S., Murakami T., Komiyama Y., Takahashi H. Association of tissue factor with a gamma chain homodimer of the IgE receptor type I in cultured human monocytes. Eur J Immunol. 1996 Oct;26(10):2529–2532. doi: 10.1002/eji.1830261037. [DOI] [PubMed] [Google Scholar]
  20. Matsuura N., Puzon-McLaughlin W., Irie A., Morikawa Y., Kakudo K., Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol. 1996 Jan;148(1):55–61. [PMC free article] [PubMed] [Google Scholar]
  21. McNamara C. A., Sarembock I. J., Gimple L. W., Fenton J. W., 2nd, Coughlin S. R., Owens G. K. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993 Jan;91(1):94–98. doi: 10.1172/JCI116206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Molloy C. J., Pawlowski J. E., Taylor D. S., Turner C. E., Weber H., Peluso M. Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the raf-1/MAP kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for an obligate autocrine mechanism promoting cell proliferation induced by G-protein-coupled receptor agonist. J Clin Invest. 1996 Mar 1;97(5):1173–1183. doi: 10.1172/JCI118531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Morris V. L., Koop S., MacDonald I. C., Schmidt E. E., Grattan M., Percy D., Chambers A. F., Groom A. C. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis. 1994 Nov;12(6):357–367. doi: 10.1007/BF01755879. [DOI] [PubMed] [Google Scholar]
  24. Mueller B. M., Reisfeld R. A., Edgington T. S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832–11836. doi: 10.1073/pnas.89.24.11832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Paborsky L. R., Caras I. W., Fisher K. L., Gorman C. M. Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem. 1991 Nov 15;266(32):21911–21916. [PubMed] [Google Scholar]
  26. Rabiet M. J., Plantier J. L., Rival Y., Genoux Y., Lampugnani M. G., Dejana E. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):488–496. doi: 10.1161/01.atv.16.3.488. [DOI] [PubMed] [Google Scholar]
  27. Rao L. V. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992 Nov;11(3-4):249–266. doi: 10.1007/BF01307181. [DOI] [PubMed] [Google Scholar]
  28. Rehemtulla A., Ruf W., Edgington T. S. The integrity of the cysteine 186-cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem. 1991 Jun 5;266(16):10294–10299. [PubMed] [Google Scholar]
  29. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996 Apr 1;15(7):1572–1582. [PMC free article] [PubMed] [Google Scholar]
  30. Rickles F. R., Hair G. A., Zeff R. A., Lee E., Bona R. D. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost. 1995 Jul;74(1):391–395. [PubMed] [Google Scholar]
  31. Ruf W., Edgington T. S. An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma. Thromb Haemost. 1991 Nov 1;66(5):529–533. [PubMed] [Google Scholar]
  32. Ruf W., Edgington T. S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J. 1994 Apr 1;8(6):385–390. [PubMed] [Google Scholar]
  33. Ruf W. Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X. Biochemistry. 1994 Sep 27;33(38):11631–11636. doi: 10.1021/bi00204a026. [DOI] [PubMed] [Google Scholar]
  34. Ruf W., Kelly C. R., Schullek J. R., Martin D. M., Polikarpov I., Boys C. W., Tuddenham E. G., Edgington T. S. Energetic contributions and topographical organization of ligand binding residues of tissue factor. Biochemistry. 1995 May 16;34(19):6310–6315. doi: 10.1021/bi00019a008. [DOI] [PubMed] [Google Scholar]
  35. Ruf W., Miles D. J., Rehemtulla A., Edgington T. S. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem. 1992 Mar 25;267(9):6375–6381. [PubMed] [Google Scholar]
  36. Ruf W., Mueller B. M. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol. 1996 Sep;3(5):379–384. doi: 10.1097/00062752-199603050-00008. [DOI] [PubMed] [Google Scholar]
  37. Sorensen B. B., Persson E., Freskgârd P. O., Kjalke M., Ezban M., Williams T., Rao L. V. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem. 1997 May 2;272(18):11863–11868. doi: 10.1074/jbc.272.18.11863. [DOI] [PubMed] [Google Scholar]
  38. Stahl A., Mueller B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 1994 Jun 1;54(11):3066–3071. [PubMed] [Google Scholar]
  39. Sugama Y., Tiruppathi C., offakidevi K., Andersen T. T., Fenton J. W., 2nd, Malik A. B. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J Cell Biol. 1992 Nov;119(4):935–944. doi: 10.1083/jcb.119.4.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Varner J. A., Cheresh D. A. Integrins and cancer. Curr Opin Cell Biol. 1996 Oct;8(5):724–730. doi: 10.1016/s0955-0674(96)80115-3. [DOI] [PubMed] [Google Scholar]
  41. Weiss L. Metastatic inefficiency. Adv Cancer Res. 1990;54:159–211. doi: 10.1016/s0065-230x(08)60811-8. [DOI] [PubMed] [Google Scholar]
  42. Zhang Y., Deng Y., Luther T., Müller M., Ziegler R., Waldherr R., Stern D. M., Nawroth P. P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994 Sep;94(3):1320–1327. doi: 10.1172/JCI117451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zioncheck T. F., Roy S., Vehar G. A. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem. 1992 Feb 25;267(6):3561–3564. [PubMed] [Google Scholar]
  44. Zucker S., Conner C., DiMassmo B. I., Ende H., Drews M., Seiki M., Bahou W. F. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem. 1995 Oct 6;270(40):23730–23738. doi: 10.1074/jbc.270.40.23730. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES